Morgan Stanley Maintains Equal-Weight on Regency Centers, Lowers Price Target to $57.5
Morgan Stanley analyst Richard Hill maintains Regency Centers (NASDAQ:REG) with a Equal-Weight and lowers the price target from $63 to $57.5.
Barclays Maintains Equal-Weight on Regency Centers, Lowers Price Target to $69
Barclays analyst Anthony Powell maintains Regency Centers (NASDAQ:REG) with a Equal-Weight and lowers the price target from $78 to $69.
Credit Suisse Initiates Coverage On Regency Centers with Neutral Rating, Announces Price Target of $56
Credit Suisse analyst Omotayo Okusanya initiates coverage on Regency Centers (NASDAQ:REG) with a Neutral rating and announces Price Target of $56.
Where Regency Centers Stands With Analysts
Analysts have provided the following ratings for Regency Centers (NASDAQ:REG) within the last quarter:
Compass Point Maintains Neutral on Regency Centers, Lowers Price Target to $67
Compass Point analyst Floris Van Dijkum maintains Regency Centers (NASDAQ:REG) with a Neutral and lowers the price target from $75 to $67.
Truist Securities Maintains Buy on Regency Centers, Lowers Price Target to $67
Truist Securities analyst Ki Bin Kim maintains Regency Centers (NASDAQ:REG) with a Buy and lowers the price target from $78 to $67.
Earnings Scheduled For May 3, 2022
Companies Reporting Before The Bell
• Kiniksa Pharmaceuticals (NASDAQ:KNSA) is projected to report earnings for its first quarter.
Where Regency Centers Stands With Analysts
Within the last quarter, Regency Centers (NASDAQ:REG) has observed the following analyst ratings: